TABLE 7.
Antiviral activity of the combination of glecaprevir with HCV inhibitors of other classes in HCV replicon cells
| Drug combinationa | Mean synergy vol ± SD (μM2 %)b | Mean antagonism vol ± SD (μM2 %)b | Interaction |
|---|---|---|---|
| Glecaprevir + IFN-α | 15 ± 1.9 | −1.1 ± 0.2 | Additive |
| Glecaprevir + RBV | 24 ± 4.9 | −2.7 ± 0.2 | Additive |
| Glecaprevir + pibrentasvir | 73 ± 17 | −1.9 ± 0.4 | Moderate synergy |
a
IFN-α, interferon alpha; RBV, ribavirin. Pibrentasvir is an HCV NS5A inhibitor.
b
Values were determined in ≥3 independent experiments.